文献速递膀胱癌与上尿路尿路上皮癌

新兴治疗时代非肌层浸润性膀胱癌的治疗选择:患者偏好研究

Treatment Selection for Non-muscle-invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study.
PubMed 文献 · Urology · 2026-02-11

该研究对美国206例自报非肌层浸润性膀胱癌(NMIBC)患者进行在线离散选择实验,评估其对疗效、安全性和给药相关治疗属性的偏好。结果显示降低进展为MIBC和NMIBC复发风险是最重要的属性,大多数患者(>70%)在固定直接选择问题中偏好保膀胱治疗而非根治性膀胱切除术,除非比较重复卡介苗治疗与RC。超过25%的受访者不同意「医生询问了我偏好的治疗选项」。

要点

  • 降低进展为MIBC和NMIBC复发风险是患者最看重的治疗属性。
  • 多数患者(>70%)偏好保膀胱治疗而非根治性膀胱切除术,但重复BCG与RC比较时除外。
  • 超过25%的患者报告医生未询问其治疗偏好,共享决策仍需加强。

核心结论

  • 降低进展为MIBC和NMIBC复发风险对治疗选择影响最大,治疗相关副作用和给药属性相对次要。
  • 多数受访者偏好具有相似临床获益的非手术治疗而非根治性膀胱切除术。
  • 有必要继续将共享决策纳入NMIBC治疗决策中。

研究设计与样本

  • 对自报NMIBC的美国患者进行在线离散选择实验调查。
  • 共206名受访者完成调查。
  • 评估疗效、安全性和给药相关治疗属性的偏好,并采用SDM-Q-9问卷评估共享决策体验。

主要发现

  • 降低进展为MIBC和NMIBC复发风险是最重要的属性。
  • 重要性依次为:需要类固醇的免疫相关副作用几率、给药方式和频率、治疗相关疲劳、泌尿系统症状或感染。
  • 在固定直接选择问题中,多数患者(>70%)偏好保膀胱治疗而非RC,但重复BCG治疗与RC比较时除外。
  • 超过25%的受访者不同意「我的医生询问了我偏好的治疗选项」这一陈述。

临床怎么用

  • 临床决策时应优先与患者沟通降低进展和复发风险的治疗获益。
  • 多数患者偏好保膀胱治疗,应在合适情况下充分讨论非手术选项。
  • 应主动询问患者治疗偏好并加强共享决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To elicit preferences for bladder-sparing treatments among patients with non-muscle-invasive bladder cancer (NMIBC) in the United States. MATERIALS AND METHODS: Patients with self-reported NMIBC completed an online discrete-choice experiment survey evaluating their preferences for efficacy-, safety-, and administration-related treatment attributes. Evidence-based attributes included NMIBC recurrence, progression to MIBC, mode and frequency of administration, fatigue, urinary symptoms or infection, and chance of immune-related side effects requiring steroids. In a series of direct-elicitation questions, respondents chose between fixed profiles of bladder-sparing treatment and radical cystectomy (RC). The 9-item Shared Decision-Making Satisfaction Questionnaire (SDM-Q-9) captured respondents' experiences and perspectives regarding involvement in shared treatment decisions with providers. RESULTS: A total of 206 respondents completed the survey. Reduced risks of progression to MIBC and NMIBC recurrence were the most important of the attributes evaluated, followed by, in order, chance of immune-related side effects requiring steroids, mode and frequency of administration, treatment-related fatigue, and urinary symptoms or infection. In fixed direct-elicitation questions, most patients (>70%) preferred bladder-sparing treatments over RC except when comparing repeated Bacillus Calmette-Guérin treatment to RC. Over 25% of respondents disagreed with the statement "My doctor asked me which treatment option I prefer" when reflecting on their shared decision-making experiences. CONCLUSION: Reduced risks of progression to MIBC and NMIBC recurrence had the greatest impacts on treatment choice; treatment-related side effects and administration-related attributes were less important. Most respondents preferred nonsurgical treatment options with similar clinical benefits over RC. Continued efforts to incorporate shared decision-making into NMIBC treatment decisions are warranted.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Smith AB, Gore JL, Chisolm S, et al. Treatment Selection for Non-muscle-invasive Bladder Cancer in an Emerging Treatment Era: A Patient Preference Study. Urology. 2026. PMID: 41687978. doi:10.1016/j.urology.2026.02.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。